Literature DB >> 24532257

Responsiveness to botulinum toxin type A in muscles of complex regional pain patients with tonic dystonia.

Johanna C M Schilder1, J Gert van Dijk, Dirk Dressler, Johannes H T M Koelman, Johan Marinus, Jacobus J van Hilten.   

Abstract

Tonic dystonia of the limbs in complex regional pain syndrome (CRPS) is associated with considerable disability. Treatment options are scarce. Botulinum toxin (BoNT) is sometimes used, but the effect is often said to be disappointing. However, this notion stems from case reports and clinicians' opinions but has never been formally studied. We therefore investigated responsiveness to BoNT in CRPS patients with tonic dystonia. We injected the extensor digitorum brevis (EDB) muscle with BoNT-A in 17 patients with CRPS and tonic dystonia to compare the response between affected and unaffected legs. We also investigated the right legs of 17 healthy controls. Responsiveness was defined as a decrease of the amplitude of the compound muscle action potential (CMAP) of >20% from baseline 2 weeks after BoNT-A injection. We controlled for a temperature effect on BoNT efficacy by measuring skin temperature hourly directly above the EDB muscle in the first 2 weeks. CMAP amplitude decreased >20% after injection on the affected side in 16 of 17 CRPS patients, similar to the response in unaffected legs (12/13) or legs of controls (17/17). The degree of CMAP reduction was significantly smaller in patients than in controls (56.0 ± 22.3 vs. 70.6 ± 14.6%; p = 0.031). This may be due to a lower physical activity level and a greater difficulty to localize the EDB muscle properly in affected legs. The decrease in CMAP amplitude was not related to skin temperature. Contrary to the prevailing opinion, BoNT-A has a normal, although perhaps slightly lower efficacy in CRPS patients with dystonia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24532257     DOI: 10.1007/s00702-014-1172-8

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  39 in total

1.  CMAP amplitude cartography of muscles innervated by the median, ulnar, peroneal, and tibial nerves.

Authors:  J G van Dijk; I van Benten; C G Kramer; D F Stegeman
Journal:  Muscle Nerve       Date:  1999-03       Impact factor: 3.217

2.  Extensor digitorum brevis test and resistance to botulinum toxin type A.

Authors:  Paul H Gordon; Clifton L Gooch; Paul E Greene
Journal:  Muscle Nerve       Date:  2002-12       Impact factor: 3.217

Review 3.  Botulinum toxin for the treatment of movement disorders.

Authors:  Mary Ann Thenganatt; Stanley Fahn
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

4.  CMAP variability as a function of electrode site and size.

Authors:  J G van Dijk; A Tjon-a-Tsien; W van der Kamp
Journal:  Muscle Nerve       Date:  1995-01       Impact factor: 3.217

5.  Pain relief is associated with improvement in motor function in complex regional pain syndrome type 1: secondary analysis of a placebo-controlled study on the effects of ketamine.

Authors:  Johanna C M Schilder; Marnix J Sigtermans; Alfred C Schouten; Hein Putter; Albert Dahan; Lucas P J J Noldus; Johan Marinus; Jacobus J van Hilten
Journal:  J Pain       Date:  2013-09-24       Impact factor: 5.820

6.  The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans.

Authors:  R Eleopra; V Tugnoli; D De Grandis
Journal:  Mov Disord       Date:  1997-01       Impact factor: 10.338

7.  Neurophysiologic aspects of patients with generalized or multifocal tonic dystonia of reflex sympathetic dystrophy.

Authors:  Willem-Johan T van de Beek; Alla Vein; Anthony A J Hilgevoord; J Gert van Dijk; Bob J van Hilten
Journal:  J Clin Neurophysiol       Date:  2002-01       Impact factor: 2.177

Review 8.  Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome.

Authors:  Alberto Esquenazi; Alberto Albanese; Michael B Chancellor; Elie Elovic; Karen R Segal; David M Simpson; Christopher P Smith; Anthony B Ward
Journal:  Toxicon       Date:  2012-12-05       Impact factor: 3.033

9.  Evidence based guidelines for complex regional pain syndrome type 1.

Authors:  Roberto S Perez; Paul E Zollinger; Pieter U Dijkstra; Ilona L Thomassen-Hilgersom; Wouter W Zuurmond; Kitty Cj Rosenbrand; Jan H Geertzen
Journal:  BMC Neurol       Date:  2010-03-31       Impact factor: 2.474

Review 10.  Regulation of peripheral blood flow in complex regional pain syndrome: clinical implication for symptomatic relief and pain management.

Authors:  George Groeneweg; Frank J P M Huygen; Terence J Coderre; Freek J Zijlstra
Journal:  BMC Musculoskelet Disord       Date:  2009-09-23       Impact factor: 2.362

View more
  5 in total

1.  [Complex regional pain syndrome (CRPS) : An update].

Authors:  V Dimova; F Birklein
Journal:  Anaesthesist       Date:  2019-02       Impact factor: 1.041

2.  [Complex regional pain syndrome (CRPS) : An update].

Authors:  V Dimova; F Birklein
Journal:  Schmerz       Date:  2018-06       Impact factor: 1.107

Review 3.  Botulinum Toxin Type A for the Treatment of Neuropathic Pain in Neuro-Rehabilitation.

Authors:  Domenico Intiso; Mario Basciani; Andrea Santamato; Marta Intiso; Filomena Di Rienzo
Journal:  Toxins (Basel)       Date:  2015-06-30       Impact factor: 4.546

Review 4.  From a Symptom-Based to a Mechanism-Based Pharmacotherapeutic Treatment in Complex Regional Pain Syndrome.

Authors:  Thomas J P Mangnus; Krishna D Bharwani; Maaike Dirckx; Frank J P M Huygen
Journal:  Drugs       Date:  2022-03-05       Impact factor: 11.431

5.  Complex regional pain syndrome-up-to-date.

Authors:  Frank Birklein; Violeta Dimova
Journal:  Pain Rep       Date:  2017-10-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.